LenexaCARE® Approved to Sell on the New Zealand Market

May 6, 2022

We are honoured and beyond excited to announce that LenexaCARE® has received our approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE). This comes not long after receiving our Australian Register of Therapeutic Goods (ARTG) approval. Our state-of-the-art technology holds the potential to mitigate costs to International Healthcare systems by providing personalised and targeted PI prevention that will alleviate the health and financial impacts of PIs.

According to the Health Quality & Safety Commision – New Zealand, pressure injuries are costing the New Zealand Healthcare System an estimated $694 million annually, affecting approximately 55,000 New Zealanders per year. The LenexaCARE® Technology is seeking to improve the standard of care for patients through preventative technology.

Since being Medsafe approved, we have recently been featured in Talking HealthTech and Pulse IT News. These featured articles spoke about pressure injuries and exciting updates within Lenexa Medical.

We are currently seeking partnership and distribution arrangements in NZ, so please feel free to reach out to the friendly team at Lenexa Medical on contactus@stg.lenexamedical.com to discuss this opportunity further.

Read the Talking HealthTech article by clicking here.

Read the Pulse IT News article by clicking here.

To learn more about Lenexa Medical, visit: https://stg.lenexamedical.com/

Interested in investing, visit: https://stg.lenexamedical.com/invest/

Contact us at: contactus@stg.lenexamedical.com


KPMG Pressure Injury Report. (2016). Retrieved 6 May 2022, from https://www.hqsc.govt.nz/resources/resource-library/new-resource-holder-page-4/